CD274 and non-small cell lung carcinoma: In the OAK study, 1225 patients with previously treated NSCLC were stratified according to PD-L1 status, number of prior chemotherapy regimens and histology before being randomised to anti-PD-L1 atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 weeks [30].